Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Tetrahydrobiopterin Stories

2014-02-04 08:35:10

- Canadian PKU and Allied Disorders encourages governments to fund PKU treatment tools as outlined by guidelines to improve outcomes in 2,000 Phenylketonuria patients - TORONTO, Feb. 4, 2014 /CNW/ - Canadian PKU and Allied Disorders (CanPKU) is extremely pleased with the clinical practice guidelines designed for the rare, inherited brain-threatening metabolic disorder Phenylketonuria (PKU), affecting about 2,000 Canadians, published online by the American College of Medical...

2014-01-31 16:23:40

PKU uncle will cycle across Canada in 71 days this summer to raise awareness and $25,000 TORONTO, Jan. 31, 2014 /CNW/ - A young father will ride his bicycle more than 7,300 kilometers coast-to-coast this summer to draw attention to a rare, brain-threatening disorder which affects his newborn niece, Avery. The Canadian PKU and Allied Disorders (CanPKU) non-profit association is proud to announce Avery's Ride for PKU. This Ride is the brainchild of Kevin Dube, of Kitchener,...

2012-01-03 08:00:00

NOVATO, Calif., Jan. 3, 2012 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2012 at 11:30 a.m. PT. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the...

2012-01-03 08:00:00

NOVATO, Calif., Jan. 3, 2012 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia is active. The company expects to initiate the Phase 1 trial in the first quarter of 2012. "BMN-111 has demonstrated benefits in moderately and severely affected animal models and has been shown to promote bone growth even in normal animals," stated Hank...

2011-12-19 08:00:00

NOVATO, Calif., Dec. 19, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for the company's manufacturing facility expansion in Novato, CA. Final approval by the EMA is expected in the first quarter of 2012, which would allow for products manufactured at the facility to be distributed in the European Union. The two Novato...

2011-12-08 11:00:00

NOVATO, Calif., Dec. 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today hosted a Research and Development Day where members of the company's management team and industry experts provided an update on BioMarin's product portfolio and advancements in the research and development pipeline. "We believe 2011 has been a year of significant progress in both our late stage and early stage clinical development programs," said Jean-Jacques Bienaime, Chief...

2011-11-30 15:00:00

NOVATO, Calif., Nov. 30, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has completed the buy back of certain intellectual property from SA Pathology, a unit of the Central Adelaide Local Health Network located in Adelaide, Australia for an upfront payment of $81 million. The intellectual property includes patents related to the purified form of Naglazyme and the method of using the enzyme in the treatment of MPS VI, which expire between...

2011-11-29 15:00:00

NOVATO, Calif., Nov. 29, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 2 study for GALNS (N-acetylgalactosamine 6-sulfatase) in patients under five years of age with mucopolysaccharidosis IVA (MPS IVA). "We expect this study to build our knowledge base in enzyme replacement therapies wherein clinicians believe earlier therapy is more impactful," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin. "Comparatively speaking,...

2011-11-28 08:00:00

NOVATO, Calif., Nov. 28, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the manufacturing facility expansion in Novato, CA. The facility will support up to $1.0 billion in revenue for BioMarin's growing enzyme replacement therapy portfolio, which is comprised of complex glycoprotein products produced by mammalian cells. "We are pleased with this first cycle approval of...

2011-11-17 08:00:00

NOVATO, Calif., Nov. 17, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Thursday, December 8, 2011 from 8:00 a.m. to 12:00 p.m. at the Four Seasons Hotel in New York City. Members of BioMarin's management team and industry experts will provide an update on the company's product portfolio and advancements in the research and development pipeline. Dial-in information Toll-free number: (877)...